Treatment | Page 180 of 465

Psychology :: Test improves prediction of self-injurious behavior

Researchers have found a better way to predict self-injurious behavior by using a test that does not rely on the individual to articulate their thoughts, but instead assesses their implicit attitudes towards self-injury. This procedure addresses a major challenge in the identification of people who engage in self-injurious behavior, because such individuals are often intentionally uncommunicative in order to avoid unwanted treatment as well as unable to articulate their feelings.

Smoking :: Spiritual beliefs, practices may help smokers quit

Unlike many traditional alcohol and drug dependence treatment programs, mainstream smoking cessation programs generally exclude spiritual practice and beliefs from the treatment process. But a study by Oregon Health & Science University Smoking Cessation Center researchers reveals many smokers are receptive to and may benefit from their own spiritual resources, when attempting to quit.

Wound :: Rapid healing with novel wound dressings

Bayer plans to enter the market for wound-healing products. Bayer Innovation GmbH ? a subsidiary of Bayer AG ? has developed a leading-edge technology for the manufacture of bioresorbable wound dressings on the basis of silica gel fibers. A ceremony was held on May 4 in Leverkusen to mark the inauguration of a pilot plant which will manufacture the wound dressing in sufficient quantities to enable clinical trials to be carried out.

Epilepsy :: Lamictal effective in treating patients with partial seizures

Data from two clinical trials presented at the American Academy of Neurology (AAN) meeting suggest that an investigational once daily extended re-lease formulation of Lamictal? (lamotrigine) is effective as add-on treatment in patients with partial epilepsy with and without secondary generalization. Lamictal XR Extended-Release Tablets are currently in development for the treatment of epilepsy. If approved, it will be the first extended release, new generation epilepsy treatment taken once-daily.

Breast Cancer :: Herceptin approved in Europe for metastatic breast cancer

Roche announced that the European Commission has approved the use of Herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.

Hepatitis B :: Raising Awareness of Chronic Hepatitis B

Bristol-Myers Squibb and the Hepatitis B Foundation announced the launch of the fourth annual “AIM for the B: Awareness, Involvement and Mobilization for Chronic Hepatitis B” program, a public education initiative taking place during National Hepatitis B Awareness Week (May 7-11).

Diabetes :: Cymbalta reduces night pain in patients with diabetic nerve pain

Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain severity were associated with less pain-related sleep interference than in those patients taking sugar pill.

Mother :: Grey’s Anatomy’s Chandra Wilson & Crest Whitestrips Daily Multicare to help moms

To celebrate hard-working moms everywhere this Mother’s Day, Chandra Wilson, star of ABC’s hit show Grey’s Anatomy, has teamed up with new Crest Whitestrips Daily Multicare in a campaign to reward multicaring moms across the country and ensure this is her brightest Mother’s Day yet.

Multiple Sclerosis :: Teva’s Laquinimod in Relapsing Remitting Multiple Sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced that data from a 36-week, randomized, doubleblind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated.

Acne :: Bayer & Intendis to co-promote YAZ for acne treatment

Bayer HealthCare Pharmaceuticals Inc, a U.S.-based pharmaceuticals unit of Bayer HealthCare., and Intendis Inc., a U.S.-based affiliate of Bayer Schering Pharma AG, Germany, announced today that they will jointly promote YAZ? (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The agreement came into effect on May 1, as part of an overall strategy to introduce dermatologists to the anti-acne benefits of YAZ.